Clinical Trials Directory

Trials / Terminated

TerminatedNCT04468490

Treatment of Breakthrough Cancer Pain According to European Guidelines

Adherence to Breakthrough Cancer Pain (BTcP) European Guidelines: an Observational Prospective Study.

Status
Terminated
Phase
Study type
Observational
Enrollment
131 (actual)
Sponsor
Aziende Chimiche Riunite Angelini Francesco S.p.A · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific predictable or unpredictable triggering factor, despite stable and adequately controlled basal pain". The present study assesses the percentage of patients who are treated according to the European guidelines (ESMO, 2018) for BTcP management in 4 European countries and the impact of the adherence to guidelines on patients' pain relief and QoL.

Detailed description

Typical BTcP episodes are of short duration (15-30 minutes/episode), moderate to severe intensity and rapid onset (maximum peak between 3-15 minutes). The best management of BTcP requires a thorough evaluation to tailor the treatment strategies. Indeed, patients with breakthrough pain should have this pain specifically assessed, starting from the appropriate diagnosis. Recently developed European guidelines support this approach and recommend treating BTcP using rapid-onset opioids (ROOs), with pharmacodynamics that mirror the quick start and short duration of the pain episode.Nevertheless, despite the drug treatment for BTcP has undergone knowledge advances in recent years and several guidelines have been published, this condition is still often inadequately managed. The present study will assess the percentage of patients who are treated according to the European guidelines for BTcP management in 4 European countries and the impact of the adherence to guidelines on patients' pain relief and QoL.

Conditions

Timeline

Start date
2020-08-11
Primary completion
2021-09-30
Completion
2021-09-30
First posted
2020-07-13
Last updated
2021-10-27

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT04468490. Inclusion in this directory is not an endorsement.